Full-Time
Regulatory Compliance Lead
Verily
1,001-5,000 employees
Precision health tech leveraging data science
Compensation Overview
$111k - $167k/yr
No H1B Sponsorship
Boston, MA, USA + 3 more
More locations: Dallas, TX, USA | Raleigh, NC, USA | San Bruno, CA, USA
Hybrid
Hybrid work is required; specific on-site frequency is not stated.
Bachelor's, Master's, PhD
 Legal & Compliance (1) |
|---|
Get referred to Verily
See people who can refer or advise you
- A bachelor's degree in engineering, computer science, statistics, or a related quantitative field and at least five years of experience in regulatory affairs within the medical device, digital health, or life sciences industry.
- Technical experience developing regulatory compliance frameworks for software as a medical device and/or artificial intelligence/machine learning-enabled products, with working knowledge of applicable Food and Drug Administration guidance including the Food and Drug Administration Quality Management System Regulation, and familiarity with ISO 13485:2016 requirements, risk management processes per ISO 14971, and medical device software lifecycle processes per IEC 62304.
- Proficiency with Google Workspace and software development and quality tools, including Jira, GitHub, and document control systems, with the ability to work directly within engineering workflows to operationalize compliance requirements.
- Strong analytical and statistical skills with experience applying quantitative methods to regulatory evaluation, performance monitoring, or post-market surveillance activities.
- Qualified applicants must not require employer-sponsored work authorization now or in the future for employment in the United States.
- Develop and maintain fit-for-purpose regulatory compliance frameworks for consumer, research, and software as a medical device products, including artificial intelligence/machine learning-enabled and generative artificial intelligence applications, in alignment with applicable United States regulations and with consideration for ex-US expansion.
- Partner with engineering, product, and quality teams to operationalize regulatory requirements throughout the product development lifecycle, leveraging Google Workspace, Jira, GitHub, and document control systems for change control, submission tracking, and compliance workflows.
- Apply statistical methods and analytical tools to support regulatory decision-making, including performance evaluation, clinical equivalence assessments, and threshold analysis for regulated products.
- Support post-market regulatory activities for artificial intelligence/machine learning-enabled products, including real-world performance monitoring, algorithmic change assessment, post-market surveillance planning, and evaluation of model drift or output degradation against predefined regulatory thresholds.
- Conduct regulatory landscape assessments for new products and markets, identify compliance risks and opportunities, and develop proactive mitigation strategies to maintain a strong regulatory posture.
- Monitor and interpret evolving regulatory guidance, including Food and Drug Administration software as a medical device, artificial intelligence/machine learning, and predetermined change control plan frameworks, and translate requirements into actionable processes and procedures for cross-functional teams.
- Author and maintain regulatory documentation, including submissions, standard operating procedures, and Design and Development File content per ISO 13485:2016, supporting both pre-market and post-market compliance activities.
- Support regulatory interactions and maintain awareness of agency expectations across applicable product domains, contributing to relationships with regulatory bodies as the product portfolio grows.
- Experience with artificial intelligence/machine learning-enabled medical device products, including familiarity with FDA artificial intelligence/machine learning software as a medical device guidance, predetermined change control plans, and post-market performance monitoring for generative artificial intelligence applications; experience using generative artificial intelligence tools such as Claude or ChatGPT to enhance regulatory and compliance workflows is a plus.
- Familiarity with Medical Device Single Audit Program audit programs and/or international regulatory frameworks such as European Union Medical Device Regulation, Health Canada, and the Therapeutic Goods Administration in support of ex-US market expansion.
- Experience supporting regulatory compliance across regulated research programs, including Good Clinical Practice and/or Good Clinical Laboratory Practice environments, clinical studies, or laboratory-developed products.
- Hands-on experience with post-market surveillance and vigilance activities for large language model or artificial intelligence/machine learning-enabled products, including real-world performance monitoring, algorithmic change assessment, and predetermined change control plan implementation.
- Experience applying statistical analysis tools such as Python, R, or equivalent to regulatory datasets, including performance benchmarking, signal detection, or equivalence testing in a regulated product context.
- An advanced degree, such as a Master of Science or Doctor of Philosophy, in engineering, statistics, computer science, or a related quantitative field, or a recognized regulatory certification such as Regulatory Affairs Certification in the United States or European Union.
Verily Life Sciences uses data science and clinical expertise to improve health outcomes through precision health. It combines medical, lifestyle, and environmental data to tailor interventions, offering products like the Baseline Platform for clinical research and COVID-19 testing, care management solutions, and medical devices. It differentiates itself by integrating diverse data at scale, pursuing health equity through Onduo, and collaborating with public sector partners while maintaining strong data security and privacy. The goal is to uncover new health insights and bring precision health to everyone, improving health outcomes across populations.
Company Size
1,001-5,000
Company Stage
Late Stage VC
Total Funding
$3.8B
Headquarters
San Francisco, California
Founded
2015
Get referred to Verily
See people who can refer or advise you
Simplify's Take
What believers are saying
- Verily raised $300 million on March 19, 2026, extending runway.
- Verily Workbench launched on AWS on April 14, 2026, widening enterprise distribution.
- Samsung Galaxy Watch and Segmed partnerships in 2026 add richer data and customers.
What critics are saying
- Alphabet lost control in March 2026, forcing Verily to justify independence fast.
- Verily cut devices in August 2025, proving management abandons lines quickly.
- AWS and Samsung deepen partner dependence; one platform shift can erase differentiation by 2027.
What makes Verily unique
- Verily Health Inc. sells governed multimodal health data workflows, not point products.
- Pre, Workbench, and Exchange link wearables, records, and AI in one stack.
- Singapore mosquito production gives Verily a rare wet-lab public-health moat.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Company Equity
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↓ -1%2 year growth
↑ 0%Verily has raised $300 million in a funding round led by Series X Capital, with participation from Alphabet, UCHealth, the University of Colorado Anschutz and others. Alphabet remains a significant minority investor but no longer holds a controlling stake in the precision health AI company. The investment marks Verily's transition from an LLC to a corporation, now officially named Verily Health Inc. The funds will accelerate its AI-native precision health platform strategy, helping customers harmonise healthcare data and deploy actionable intelligence into research and care workflows. Verily recently announced partnerships with Samsung's Galaxy Watch and Salesforce's Agentforce Health. The company, which graduated from Google X 10 years ago as one of Alphabet's earliest ventures, aims to make healthcare more personalised, predictive and precise through AI-powered solutions.
Verily, a Google subsidiary, expands its mosquito factory in Singapore to strengthen dengue control. 26 May 2026 [PHOTO: The Straits Times] Market Info | Health & Lifestyle | Public Health Date: 1 June 2026 Region: ASEAN-O Country: Singapore Sector: Health & Lifestyle Sub-sector: Public Health Section: Market Trends Theme: Combating Infectious Diseases Verily, a subsidiary of tech giant Google, has announced a significant expansion of its sterile mosquito production facility in Singapore, marking a major milestone in the fight against dengue. This initiative leverages cutting-edge technology where sterile male mosquitoes are bred and released into the wild to mate with wild females, thereby reducing the population of mosquitoes capable of transmitting diseases like dengue. This method, known as the Sterile Insect Technique (SIT), is an eco-friendly alternative to traditional pesticides and aligns with a sustainable approach to vector control. The expansion of this facility in Singapore reflects the country's commitment to strengthening its public health capabilities in the face of challenges posed by vector-borne diseases. Dengue, in particular, remains a major concern in the region, with thousands of cases reported annually. By adopting this innovative technology, Singapore demonstrates its determination to combine science and public health to protect its population. This approach also aligns with the broader objectives of the Healthier SG strategy, which aims to enhance the resilience of the healthcare system against emerging threats. Furthermore, this initiative positions Singapore as a regional leader in biotechnology applied to public health. By collaborating with international players like Verily, the country strengthens its ability to innovate and attract investments in sustainable health solutions. Verily's sterile mosquito factory in Singapore could also serve as a model for other countries in the region facing similar challenges with mosquito-borne diseases. This expansion is a tangible example of how Singapore is leveraging technology and innovation to address complex public health challenges while contributing to global solutions for infectious disease control.
Segmed, Verily band together to expand access to real-world imaging data. Pairing aims to to support patient-centered, data-driven healthcare innovation. April 30, 2026 Managing Editor Segmed Inc. is partnering with Verily to increase access to de-identified imaging datasets. Through the collaboration, Segmed is making its de-identified, diagnostic-grade imaging and associated clinical data more available by enabling researchers to explore curated datasets within Verily's precision health platform, Pre Exchange and Workbench environment, secure platforms designed to accelerate precision health research and discovery. The partnership reflects Segmed's commitment to supporting rigorous, privacy-first research while lowering barriers to entry for investigators across academia, life sciences, and healthcare artificial intelligence (AI), Segmed executives claim. "Advanced imaging data plays a critical role in precision medicine, particularly when combined with clinical and other biomedical data modalities," Segmed CEO David Gascoigne said. "By partnering with Verily, we're expanding responsible access to high-quality, de-identified imaging datasets, helping researchers generate insights faster to accelerate the development of diagnostics and therapies." Segmed's initial dataset available through Pre Exchange focuses on breast cancer and includes a longitudinal cohort of patients who underwent at least one digital breast tomosynthesis (DBT) exam and biopsy-proven malignant lesions. This dataset is drawn from Segmed's broader global imaging platform, which includes approximately 150 million de-identified imaging exams spanning modalities such as CT, MRI, X-ray, ultrasound, mammography, PET, SPECT, echocardiography, and DEXA. "This partnership with Segmed is an important step forward in advancing AI-powered precision health," Verily Chief Revenue Officer Bharat Rajagopal stated. "By integrating Segmed's curated real-world imaging and associated clinical data into Pre, we are empowering researchers with the comprehensive, multimodal data resources they need to unlock new insights and accelerate discovery." This partnership reflects Segmed's ongoing efforts to support patient-centered, data-driven healthcare innovation by enabling secure, scalable access to real-world imaging data and associated clinical data within trusted research environments. Segmed Inc. streamlines access to diverse, high-quality real-world data, including medical imaging and clinical records, for biopharmaceutical R&D, AI development, and medical device innovation. With a global network of healthcare partners across five continents, Segmed provides researchers with approximately 150 million de-identified, standardized imaging datasets through its proprietary platform, empowering safer, faster, and more equitable healthcare advancements. Verily is a data platform and technology company purpose-built to power AI for precision health. Verily offers AI-enabled solutions that transform multimodal health data into insights and actions that accelerate research and improve care for individuals and communities. Verily is positioned at the intersection of technology, data science, and healthcare to create tools that accelerate evidence generation, enable more personalized care, and help manage disease at a population level.
Verily Health has announced that Verily Workbench, its scalable trusted research environment for biomedical data analysis and AI development, is now generally available on Amazon Web Services. The platform enables researchers to analyse healthcare data with built-in compliance and integrated AI tools. Workbench offers zero cloud cost markup, allowing organisations to use existing AWS accounts and negotiated rates. The platform includes native integration with NVIDIA AI tools and supports multicloud operations across AWS and Google Cloud Platform. Researchers can access free standard tier accounts through Verily's Exchange solution. The platform currently serves life sciences, health system and government customers, including the NIH's All of Us Research Programme, which supports over 20,000 researchers worldwide. Verily holds SOC 2 Type 2 and ISO/IEC 27001 certifications.
Dallas-Based Verily raises $300M, ending Alphabet's controlling stake. Verily graduated from Google X 10 years ago as one of Alphabet's earliest "Other Bets," focusing on breakthrough science and health tech innovation. Its new round was led by Series X Capital, with participation from Alphabet, UCHealth, the University of Colorado Anschutz, and other investors. The lobby of Verily's headquarters at Cypress Waters in Dallas. [Photo: Verily] Dallas-based Verily has raised a new $300 million investment round led by Series X Capital, with participation from Alphabet, UCHealth, the University of Colorado Anschutz, and other investors, for the next phase of its precision health AI strategy. With this funding round, Alphabet will now be a significant minority investor in Verily, while no longer having a controlling stake. "Today is an important step in our mission to bring the promise of precision health to everyone," said Stephen Gillett, chairman and CEO of Verily,. "From research to care, our customers need solutions that bring the best of clinical and scientific rigor together with AI to deliver the next generation of healthcare - one that is as precise as it is personal." "Series X Capital, Alphabet, UCHealth, the University of Colorado Anschutz and our many investors will be fantastic partners in this transformation of healthcare," Gillett added in a statement. With the investment, Verily has transitioned its legal structure from an LLC to a corporation, and will now operate as Verily Health Inc. The company said it aims to boost its AI-native precision health platform strategy and roadmap to help customers streamline their healthcare data, while modeling and deploying actionable intelligence into research and care workflows. Verily is headquartered in the Cypress Waters development in Dallas, just southeast of Coppell. The company relocated its HQ from South San Francisco in 2024, bridging its East and West Coast operations in North Texas while maintaining its presence in the Bay Area. Using AI to transform healthcare. Recently, Verily has established several commercial partnerships, including a new collaboration with Samsung's Galaxy Watch to help life sciences customers advance clinical research through biomarker development on the Pre platform. The company has also announced a strategic partnership with Salesforce for the integration of the Verily Pre Platform with Agentforce Health to fuel enterprise precision health solutions. Verily said the new partnerships are strengthened by its recent collaboration with UCHealth, the University of Colorado Anschutz, and RefinedScience, who are using the Verily Pre platform for AI-driven research and care transformation. Gideon Yu, founder and managing partner of Series X Capital, said his firm "was established in collaboration with Google's X, The Moonshot Factory, to scale moonshot technologies into consequential, world-changing companies." He added that his firm is "extremely excited to lead this milestone round for Verily, as they drive commercial momentum as a leader in precision health." 'A generational opportunity' Graduating from Google X 10 years ago as one of Alphabet's earliest "Other Bets," Verily focuses on breakthrough science and health tech innovation. "At Alphabet, we applaud Verily's tenacity in using technology to address longstanding challenges in the healthcare industry," said Ruth Porat, president and. chief investment officer at Alphabet and Google. "Bringing in new investors, alongside Alphabet's ongoing involvement, enables Verily to further scale the business to help improve patient outcomes and lower the cost of healthcare delivery through their AI health platform." Richard Zane, MD, UCHealth chief medical and innovation Officer, said that collaborating with Verily to craft a data framework "creates a generational opportunity" to improve medicine. "This collaboration helps unlock the long-promised potential of personalized care," Zane added, "benefiting our patients and, ultimately, all patients. It will save lives, and we're eager to get started." Other recent moves by Verily. Last October, Verily launched a new consumer health app, Verily Me, designed to close gaps in care and enable people to stay informed and engaged in their health journey over time. Last April, Verily received a $14.7 million grant from The Michael J. Fox Foundation for Parkinson's Research. The grant's goal is to generate a comprehensive molecular dataset to advance Parkinson's disease research. Track Dallas-Fort Worth's business and innovation landscape with its curated news in your inbox Tuesday-Thursday. One quick signup, and you're done. R E A D N E X T. * The Last Word: Arete Health CEO On a First-of-Its-Kind Health and Wellness Program for Dallas Creatives Creatives Care Dallas brings virtual care, behavioral health, 2,000+ medications with zero copay, and more to Dallas County's gig workers. The community initiative is powered by Arete Health Shield in partnership with the Dallas Music Office. * Calendar: Not-to-Miss Events for Innovators in Dallas-Fort Worth North Texas has plenty to see, hear, and watch. Here are its editors' picks. Plus, you'll find more selections to "save the date." * Alphabet-Owned Verily Launches AI-Powered App to Manage Healthcare and Personalize Insights Unveiled at HLTH USA 2025, the Dallas-based precision health company's Verily Me app blends clinical guidance and AI-driven tools to help people stay informed, connected, and proactive in managing their health. * North Texas Innovation Is Boundary-Breaking. Nominations for the Awards That Prove It Close Sept. 12 D CEO and Dallas Innovates have expanded The Innovation Awards 2026 with more individual and company categories this year. Now is your chance to be part of the region's defining recognition for innovators. * SVP Dallas Names Catherine Cuellar as Its Next CEO A familiar figure in Dallas arts, civic innovation, and public service, Cuellar will succeed longtime CEO Tony Fleo following a months-long search as Social Venture Partners Dallas plans its next 25 years. Share via: